Inhibition of cyclooxygenase-1 and cyclooxygenase-2: Analysis of in vitro test systems and their clinical relevance

Journal of Clinical Rheumatology

Volumn 4, Issue 5 SUPPL., 1998, Pages

  Pairet, Michel ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Cyclooxygenase inhibitor; In vitro assays; NSAIDs

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLOSULIDE; FLURBIPROFEN; IBUPROFEN; KETOPROFEN; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULINDAC;

ANTIINFLAMMATORY ACTIVITY; CELL IMMORTALIZATION; CONCENTRATION RESPONSE; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS;

EID: 0031772057     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124743-199810001-00004     Document Type: Conference Paper

References (49)

1. 2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265:16737-40.
2. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991;88:2692-6.
3. Vane J. Towards a better aspirin. Nature 1994; 367:215-16.
4. Pairet M, Engelhardt G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fundam Clin Pharmacol 1996;10:1-15.
5. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1994;90:11693-7.
6. Engelhardt G, Bögel R, Schnitzler C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part I: In vitro findings. Biochem Pharmacol 1996;51:21-8.
7. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new antiinflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994; 47:55-9.
8. Klein T, Nüsing RM, Wiesenberg-Boettcher I, Ullrich V. Mechanistic studies on the selective inhibition of cyclooxygenase-2 by indanone derivatives. Biochem Pharmacol 1996;51:285-90.
9. Vago T, Bevilacqua M, Norbiato G. Effect of nimesulide action time dependence on selectivity towards prostaglandin G/H synthase/ cyclooxygenase activity. Arzneimittelforschung/Drug Res 1995;45:1096-8.
10. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-14.
11. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A 1994;91:12013-17.
12. Prasit P, Black WC, Chan C-C, Ford-Hutchinson AW, Gauthier JY, Gordon R, et al. L-745,337: a selective cyclooxygenase-2 inhibitor. Med Chem Res 1995;5:364-74.
13. Copeland RA, Williams JM, Giannaras J, Nurnberg S, Covington M, Pinto D, et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci U S A 1994;91: 11202-6.
14. O'Neill GP, Mancini JA, Kargman S, Yergey J, Kwan MY, Falgueyret JP, et al. Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol Pharmacol 1994;45:245-54.
15. Glaser K, Sung M-L, O'Neill K, Belfast M, Hartman D, Carlson R, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995;281:107-11.
16. Churchill L, Graham AG, Shih C-K, Pauletti D, Farina PR, Grob PM. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharmacology 1996;4:125-35.
17. Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J 1995;305:479-84.
18. Laneuville O, Breuer DK, Dewitt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994;271: 927-34.
19. Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 1997;121:105-17.
20. Kargman S, Wong E, Grieg GM, Falgueyret JP, Cromlish W, Ethier D, et al. Mechanism of selective inhibition of human prostaglandin G/ H synthase-1 and -2 in intact cells. Biochem Pharmacol 1996;52:1113-25.
21. Barnett J, Chow J, Ives D, Chiow M, MacKenzie R, Osen E, et al. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1994;1209:130-9.
22. Grossman CJ, Wiseman J, Lucas FS, Trevethick MA, Birch PJ. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDS and Cox 2 inhibitors. Inflamm Res 1995;44:253-7.
23. 2 production. Inflamm Res 1996;45:246-53.
24. Brideau C, Kargman S, Liu S, Dallab AL, Ehrich EW, Rodger JW, et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 1996;45:68-74.
25. Pairet M, Lidbury PS, Engelhardt G, Trummlitz G, Vane JR. Meloxicam: cyclooxygenase selectivity, anti-inflammatory activity and gastric and renal safety. Inflamm Res 1995;44(suppl 3):S274.
26. Euler US v. Zur Kenntnis der pharmakologischen Wirkungen von Nativsekreten und Extrakten männlicher accessorischer Geschlechtsdrüsen. Arch Exp Path Pharmakol 1934;975:78-84.
27. Goldblatt MW. Properties of human seminal plasma. J Physiol (Lond) 1935;84:208-18.
28. Sirois J, Simmons DL, Richards JS. Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide H synthase in rat preovulatory follicles. Induction in vivo and in vitro. J Biol Chem 1992;267:11586-92.
29. Slater D, Berger L, Newton R, Moore G, Bennett P. The relative abundance of type 1 to type 2 cyclo-oxygenase mRNA in human amnion at term. Biochem Biophys Res Commun 1994;198:304-8.
30. Cromlish WA, Kennedy BP. Selective inhibition of cyclooxygenase-1 and -2 using intact insect cell assays. Biochem Pharmacol 1996;52: 1777-85.
31. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994;271:1705-12.
32. Patrignani P, Panara MR, Santini G, Sciulli MG, Padorano R, Cipollone F, et al. Differential inhibition of the cyclooxygenase activity of prostaglandin endoperoxide synthase isozymes in vitro and ex vivo in man. Prostaglandins Leukot Essent Fatty Acids 1996; 55(suppl 1). Abstract P115.
33. Day RO, Francis H, Vial J, Geisslinger G, Williams KM. Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations. J Rheumatol 1995;22: 2295-303.
34. Hudson N, Balsitis M, Filipowicz F, Hawkey CJ. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993;34:748-51.
35. 2α content and on gastric mucosal injury in humans receiving fish oil or olive oil. Gastroenterology 1990;98:586-91.
36. Taha AS, McLaughlin S, Holland PJ, Kelly RW, Sturrock RD, Russell RI. Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis. Ann Rheum Dis 1990;49:354-8.
37. Bertin P, Lapicque F, Payan E, Rigaud M, Bailleul F, Jaeger S, et al. Sodium naproxeru concentration and effect on inflammatory response mediators in human rheumatoid synovial fluid. Eur J Clin Pharmacol 1994;46:3-7.
38. Hayllar J, Bjarnason I. NSAIDs, Cox-2 inhibitors, and the gut. Lancet 1995;346:521-2.
39. Rabasseda X. Nimesulide: a selective cyclooxygenase 2 inhibitor antiinflammatory drug. Drugs Today 1996;32(suppl D):1-23.
40. Türck D, Busch U, Heinzel G, Narjes H. Clinical pharmacokinetics of meloxicam. Arzneimittelforschung/Drug Res 1997;47:253-8.
41. Stichtenoth DO, Wagner B, Frölich JC. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. J Investig Med 1997;45:44-9.
42. Davis R, Brodgen RN. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994;48:431-54.
43. Theiss U, Timmer W, Wieckhorst G, Macciocchi A, Wetzelsberger N. Investigation into a possible drug-drug interaction between warfarin and nimesulide in healthy volunteers. Meth Find Exp Clin Pharmacol 1993;15: 629-35.
44. Cullen L, Kelly L, Coyle D, Forde R, Fitzgerald D. Selective suppression of COX-2 during chronic administration of nimesulide in man. In: William Harvey Research Conference: Selective COX-2 inhibitors: pharmacology, clinical effects and therapeutic potential. Cannes, France, March 20-21, 1997. Abstract.
45. Frölich JC. A classification of NSATDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol Sci 1997;18:30-4.
46. Rainsford KD, Ginsburg I, Gadd SJ. A comparison between the effects of meloxicam and other NSAIDs on the production of oxyradicals by human polymorphonuclear leucocytes. Inflammopharmacology 1997;5:9-19.
47. Fiebich BL, Lieb K, Hüll M, Berger M, Bauer J. Effects of NSAIDs on IL-1β-induced IL-6 mRNA and protein synthesis in human astrocytoma cells. NeuroReport 1996;7:1209-1213.
48. García-Vicuña R, Díaz-González F, González-Alvaro I, del Pozo MA, Mollinedo F, Cabanas C, et al. Prevention of cytokine-induced changes in leukocyte adhesion receptors by nonsteroidal antiinflammatory drugs from the oxicam family. Arthritis Rheum 1997;40:143-53.
49. Mahmud T, Scott DL, Bjarnason I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann Rheum Dis 1996;55:211-13.